Patents by Inventor Jennifer BORDEAUX
Jennifer BORDEAUX has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11747319Abstract: The invention relates, in part, to systems and methods for scoring a sample containing tumor tissue from a cancer patient. The score is representative of a nearness between at least one pair of cells, a first member of the least one pair of cells expressing a first biomarker and a second member of the at least one pair of cells expressing a second biomarker that is different from the first biomarker. The score obtained from these methods can be indicative of a likelihood that a patient may respond positively to immunotherapy.Type: GrantFiled: February 14, 2022Date of Patent: September 5, 2023Assignee: Novartis AGInventors: Brian Little, Jennifer Bordeaux
-
Patent number: 11726092Abstract: The invention relates, in part, to methods of scoring a sample containing tumor tissue from a cancer patient. The score is representative of a spatial proximity between at least one pair of cells, a first member of the at least one pair of cells expressing a first biomarker and a second member of the at least one pair of cells expressing a second biomarker that is different from the first biomarker. The score obtained from these methods can be indicative of a likelihood that a patient may respond positively to immunotherapy.Type: GrantFiled: June 2, 2020Date of Patent: August 15, 2023Assignee: Novartis AGInventors: Naveen Dakappagari, Thai Tran, Brian Little, Ju Young Kim, Jennifer Bordeaux
-
Publication number: 20230017087Abstract: The invention relates, in part, to methods of deriving a value for % biomarker positivity (PBP) for all cells or optionally, one or more subsets thereof, present in a field of view of a tissue sample from a cancer patient. The values for PBP can be indicative of a patient's response to immunotherapy.Type: ApplicationFiled: September 20, 2022Publication date: January 19, 2023Applicant: Novartis AGInventors: Naveen DAKAPPAGARI, Jennifer BORDEAUX, Thai TRAN, Ju Young KIM
-
Patent number: 11480570Abstract: The invention relates, in part, to methods of deriving a value for % biomarker positivity (PBP) for all cells or optionally, one or more subsets thereof, present in a field of view of a tissue sample from a cancer patient. The values for PBP can be indicative of a patient's response to immunotherapy.Type: GrantFiled: October 21, 2016Date of Patent: October 25, 2022Assignee: NOVARTIS AGInventors: Naveen Dakappagari, Jennifer Bordeaux, Thai Tran, Ju Young Kim
-
Patent number: 11430111Abstract: The invention relates, in part, to systems and methods for scoring a sample containing tumor tissue from a cancer patient. The score obtained from these methods can be indicative of a likelihood that a patient may respond positively to immunotherapy. The invention also relates, in part, to methods of deriving a value for % biomarker positivity (PBP) for all cells or optionally, one or more subsets thereof, present in a field of view of a tissue sample from a cancer patient. The values for PBP can be indicative of a patient's response to immunotherapy.Type: GrantFiled: March 18, 2020Date of Patent: August 30, 2022Assignee: Novartis AGInventors: Brian Little, Jennifer Bordeaux
-
Publication number: 20220170905Abstract: The invention relates, in part, to systems and methods for scoring a sample containing tumor tissue from a cancer patient. The score is representative of a nearness between at least one pair of cells, a first member of the least one pair of cells expressing a first biomarker and a second member of the at least one pair of cells expressing a second biomarker that is different from the first biomarker. The score obtained from these methods can be indicative of a likelihood that a patient may respond positively to immunotherapy.Type: ApplicationFiled: February 14, 2022Publication date: June 2, 2022Applicant: Novartis AGInventors: Brian Little, Jennifer BORDEAUX
-
Patent number: 11249066Abstract: The invention relates, in part, to systems and methods for scoring a sample containing tumor tissue from a cancer patient. The score is representative of a nearness between at least one pair of cells, a first member of the least one pair of cells expressing a first biomarker and a second member of the at least one pair of cells expressing a second biomarker that is different from the first biomarker. The score obtained from these methods can be indicative of a likelihood that a patient may respond positively to immunotherapy.Type: GrantFiled: June 10, 2020Date of Patent: February 15, 2022Assignee: Novartis AGInventors: Brian Little, Jennifer Bordeaux
-
Publication number: 20200300834Abstract: The invention relates, in part, to systems and methods for scoring a sample containing tumor tissue from a cancer patient. The score is representative of a nearness between at least one pair of cells, a first member of the least one pair of cells expressing a first biomarker and a second member of the at least one pair of cells expressing a second biomarker that is different from the first biomarker. The score obtained from these methods can be indicative of a likelihood that a patient may respond positively to immunotherapy.Type: ApplicationFiled: June 10, 2020Publication date: September 24, 2020Applicant: Novartis AGInventors: Brian Little, Jennifer Bordeaux
-
Publication number: 20200292550Abstract: The invention relates, in part, to methods of scoring a sample containing tumor tissue from a cancer patient. The score is representative of a spatial proximity between at least one pair of cells, a first member of the at least one pair of cells expressing a first biomarker and a second member of the at least one pair of cells expressing a second biomarker that is different from the first biomarker. The score obtained from these methods can be indicative of a likelihood that a patient may respond positively to immunotherapy.Type: ApplicationFiled: June 2, 2020Publication date: September 17, 2020Applicant: Novartis AGInventors: Naveen DAKAPPAGARI, Thai TRAN, Brian LITTLE, Ju Young KIM, Jennifer BORDEAUX
-
Publication number: 20200286230Abstract: The invention relates, in part, to systems and methods for scoring a sample containing tumor tissue from a cancer patient. The score obtained from these methods can be indicative of a likelihood that a patient may respond positively to immunotherapy. The invention also relates, in part, to methods of deriving a value for % biomarker positivity (PBP) for all cells or optionally, one or more subsets thereof, present in a field of view of a tissue sample from a cancer patient. The values for PBP can be indicative of a patient's response to immunotherapy.Type: ApplicationFiled: March 18, 2020Publication date: September 10, 2020Applicant: Novartis AGInventors: Brian LITTLE, Jennifer BORDEAUX
-
Patent number: 10712331Abstract: The invention relates, in part, to systems and methods for scoring a sample containing tumor tissue from a cancer patient. The score is representative of a nearness between at least one pair of cells, a first member of the least one pair of cells expressing a first biomarker and a second member of the at least one pair of cells expressing a second biomarker that is different from the first biomarker. The score obtained from these methods can be indicative of a likelihood that a patient may respond positively to immunotherapy.Type: GrantFiled: October 21, 2016Date of Patent: July 14, 2020Assignee: Novartis AGInventors: Brian Little, Jennifer Bordeaux
-
Patent number: 10705088Abstract: The invention relates, in part, to methods of scoring a sample containing tumor tissue from a cancer patient. The score is representative of a spatial proximity between at least one pair of cells, a first member of the at least one pair of cells expressing a first biomarker and a second member of the at least one pair of cells expressing a second biomarker that is different from the first biomarker. The score obtained from these methods can be indicative of a likelihood that a patient may respond positively to immunotherapy.Type: GrantFiled: October 21, 2016Date of Patent: July 7, 2020Assignee: NOVARTIS AGInventors: Naveen Dakappagari, Thai Tran, Brian Little, Ju Young Kim, Jennifer Bordeaux
-
Patent number: 10621721Abstract: The invention relates, in part, to systems and methods for scoring a sample containing tumor tissue from a cancer patient. The score obtained from these methods can be indicative of a likelihood that a patient may respond positively to immunotherapy. The invention also relates, in part, to methods of deriving a value for % biomarker positivity (PBP) for all cells or optionally, one or more subsets thereof, present in a field of view of a tissue sample from a cancer patient. The values for PBP can be indicative of a patient's response to immunotherapy.Type: GrantFiled: October 21, 2016Date of Patent: April 14, 2020Assignee: NOVARTIS AGInventors: Brian Little, Jennifer Bordeaux
-
Publication number: 20200049714Abstract: The invention relates, in part, to methods of predicting a likelihood that a cancer patient will respond positively to immunotherapy. The methods include scoring a sample containing tumor tissue from a cancer patient, wherein the score is representative of a spatial proximity between at least one pair of cells, a first member of the at least one pair of cells expressing a first biomarker and a second member of the at least one pair of cells expressing a second biomarker that is different from the first biomarker, and deriving a value for % biomarker positivity (PBP) for all cells or optionally, one or more subsets thereof, present in a field of view of a tissue sample from the cancer patient.Type: ApplicationFiled: February 5, 2018Publication date: February 13, 2020Applicant: Novartis AGInventors: Jennifer BORDEAUX, Naveen DAKAPPAGARI, Ju Young KIM
-
Publication number: 20190293648Abstract: The invention relates, in part, to methods of deriving a value for % biomarker positivity (PBP) for all cells or optionally, one or more subsets thereof, present in a field of view of a tissue sample from a cancer patient. The values for PBP can be indicative of a patient's response to immunotherapy.Type: ApplicationFiled: October 21, 2016Publication date: September 26, 2019Applicant: Novartis AGInventors: Naveen DAKAPPAGARI, Jennifer BORDEAUX, Thai TRAN, Ju Young KIM
-
Publication number: 20190056404Abstract: The invention relates, in part, to methods of scoring a sample containing tumor tissue from a cancer patient. The score is representative of a spatial proximity between at least one pair of cells, a first member of the at least one pair of cells expressing a first biomarker and a second member of the at least one pair of cells expressing a second biomarker that is different from the first biomarker. The score obtained from these methods can be indicative of a likelihood that a patient may respond positively to immunotherapy.Type: ApplicationFiled: October 21, 2016Publication date: February 21, 2019Applicant: Novartis AGInventors: Naveen DAKAPPAGARI, Thai TRAN, Brian LITTLE, Ju KIM, Jennifer BORDEAUX
-
Publication number: 20180330498Abstract: The invention relates, in part, to systems and methods for scoring a sample containing tumor tissue from a cancer patient. The score obtained from these methods can be indicative of a likelihood that a patient may respond positively to immunotherapy. The invention also relates, in part, to methods of deriving a value for % biomarker positivity (PBP) for all cells or optionally, one or more subsets thereof, present in a field of view of a tissue sample from a cancer patient. The values for PBP can be indicative of a patient's response to immunotherapy.Type: ApplicationFiled: October 21, 2016Publication date: November 15, 2018Applicant: Novartis AGInventors: Brian LITTLE, Jennifer BORDEAUX
-
Publication number: 20180306768Abstract: The invention relates, in part, to systems and methods for scoring a sample containing tumor tissue from a cancer patient. The score is representative of a nearness between at least one pair of cells, a first member of the least one pair of cells expressing a first biomarker and a second member of the at least one pair of cells expressing a second biomarker that is different from the first biomarker. The score obtained from these methods can be indicative of a likelihood that a patient may respond positively to immunotherapy.Type: ApplicationFiled: October 21, 2016Publication date: October 25, 2018Applicant: Novartis AGInventors: Brian LITTLE, Jennifer BORDEAUX